Objectives Health Technology Assessment (HTA) agencies produce recommendations that guide public funding of pharmaceuticals, based on various criteria. We explored factors that may contribute to explaining differences in coverage decisions by the National Institute for Health and Care Excellence (NICE) in England and Wales, the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekeringen (CVZ), and the French Haute Autorité de Santé (HAS). Methods A dataset of 977 HTA decisions made in 2004-2009 was created. A three-category outcome variable was used (decision to 'recommend', 'restrict' or 'not recommend' a technology). Multivariate analyses explored impacts of clinical, economic, process and socio-economic variables in their decision making. Results Relative to the CVZ and adjusting for a range of confounders, technologies were more likely to be recommended by NICE and HAS, and restricted or not-recommended by the SMC. Recommendation was significantly associated (p B 0.10) with several variables: strength of clinical evidence (number of trials, use of active comparator-arm, demonstration of clinical superiority) orphan status and indication for cancer. Simultaneous assessment of multiple rather than single pharmaceuticals was associated with increased probability of restriction. Conclusions In this European multi-HTA study, appraisal outcomes differed significantly across HTA bodies. A range of evidence and non-evidence factors were associated with HTA decisions, confirming the value of comprehensive, multivariate analyses. Nevertheless, a large proportion of variance in HTA decisions remained unexplained, suggesting that greater transparency of decision making is needed, along with associated further research.
Introduction
The health technology assessment (HTA) decision-making process is prominent in several European countries, and advises healthcare systems on the appropriate use of pharmaceuticals (among other technologies) and whether they should be recommended for public funding. HTA decisions have an impact on clinicians and patients by defining to whom a medicine can be made available, for how long, at what price and under what circumstances or conditions. Thus HTA decisions represent a key point within the complex decision-making process that governs funding and access for pharmaceuticals in some countries.
Because HTA decisions have a significant impact on patient care, transparency around HTA decision making is highly important. For example, the European Commission [1] has launched an up-date of the EU Transparency Directive (89/105/EEC) to further emphasise this notion. The proposed amendment from the European Commission now includes direct reference to the concept of transparency and proposes that determination of price and access requires ''transparent, objective and verifiable criteria'' (p. 11).
It is within this context that we examine the impact of a range of evidence, process and socio-economic factors on HTA decisions and public funding of pharmaceuticals in a selection of European countries, namely UK, France, and the Netherlands:
• National Institute for Health and Care Excellence (NICE), England and Wales, • Scottish Medicines Consortium (SMC), Scotland, • College voor Zorgverzekeringen (CVZ), the Netherlands, • Haute Autorité de Santé (HAS), France.
Descriptions of these four HTA bodies are provided as supplementary digital material (part 1).
Specifically, the analysis aimed to (1) assess whether these HTA bodies differ amongst themselves in terms of the coverage decisions they make, while adjusting for a range of confounding factors; and (2) explore the factors that contribute to explaining the variability in coverage decisions made by the four HTA bodies in 2004-2009.
Methods

Explanatory Variables
It was hypothesised, based on the nature of the HTA bodies selected and the literature available, that decisions are driven by the HTA decision-making process itself, the evidence considered within that process, and by the socioeconomic and political context in which decisions are made (further information provided as supplementary material, part 2). Research has shown that the evidence related to the medicine under review (whether clinical, economic or otherwise) can have an impact on HTA decisions [2] [3] [4] [5] [6] [7] [8] . The literature examining the HTA appraisal process provides insights into a number of process-related factors that can potentially influence decisions [9] [10] [11] [12] . Indeed, reference in the literature is made to the impact of broader healthcare and welfare characteristics on HTA decision making, such as healthcare spending per capita, societal willingness to pay, the structure of the healthcare system, as well as ethical and social considerations [13] [14] [15] [16] [17] . In line with the hypothesised drivers of HTA decision making, 29 variables were identified, shown in Table 1 .
Sample
The choice of HTA body included in the analysis aimed to maximise the chance of obtaining useful data to address the research question, provide a comprehensive platform for analysis of the research question rather than the examination of a particular factor in isolation, and to allow for the exploration of variation in the implementation and drivers of HTA decision making. To gather information on variables related to the coverage decision for specific technologies, data were required from HTA bodies that published their appraisal decisions and rationale for those decisions in a comprehensive format that was accessible to the public. To this end, pharmaceutical technology appraisals performed by NICE, SMC, CVZ and HAS were selected to provide the sample for this analysis. To capture a sufficient number of appraisals for both individual and aggregate analyses, a 5-year time horizon was implemented. Data extraction by one of the authors (KC) took place in July 2008-December 2009. The sample included all drug technology appraisals (as opposed to medical devices or other interventions) made during the period January 2004-June 2009, indicated for an adult population (aged over 17 years). Technology appraisals were excluded from the analysis for any of the following reasons: if they focused on a non-adult population; if they appraised nondrug interventions; if marketing authorisation was withdrawn; if the Amélioriation du Service Médicale Rendu (ASMR) rating was not reported (HAS only); if an abbreviated or independent review panel (IRP) guidance was issued (SMC only); or if the full guidance was not available.
The French HAS issued 2600 recommendations in [2004] [2005] [2006] [2007] [2008] [2009] . Given resource constraints, it was not possible to review all of these recommendations, thus the HAS sample was restricted to technologies appraised by SMC/ 
Numeric
Measures the percentage probability of acceptance at the threshold used by the agency. For the CVZ the probability of the medication being cost-effective was reported at a EUR €50,000 threshold; for NICE and SMC, a threshold of 20,000 GBP was used. This variable was not applicable to the HAS NICE. While it is understood that this approach may lead to selection bias, the benefit derived was that it increased the opportunity for comparability across agencies, by collecting information on a common list of compounds and streamlining data extraction to those appraisals that were relevant for the research question. A data extraction form was developed to extract information from public data sources to ensure transparency, reproducibility and consistency. The resulting extracted data was coded and prepared for analysis. The variable definitions and data sources used are shown in Table 1 .
Outcome Variable
To determine the appropriate outcome variable, the approach to decision making was assessed for each HTA body. In the period 2004-2009, HAS used a five-point scale known as the ASMR rating, that classified a technology according to the level of incremental medical service rendered, with the highest level (I) indicating a high incremental medical service and the lowest (V) denoting no additional medical benefit. Subsequent pricing and volume negotiations were then based on these ratings. Similarly, the CVZ has several possible HTA options in its armamentarium: the GVS 1A or In all four HTA bodies, decisions are based on more than a binary decision process. This was a key justification for developing a non-binary modelling approach. In addition, previously published analyses have also utilised non-binary approaches [6, 18] . The analysis used a standardised three-category outcome variable where the new technology could be:
• recommended for routine use,
• recommended for restricted use,
• not recommended for use.
Our analysis focuses on the HAS and its decision making. Technologies with an ASMR V are considered 'not recommended' because the HAS did not find any evidence to suggest that the technology would offer incremental value relative to alternative treatment options. In other words, with an ASMR V, the HAS signals that it finds no basis upon which to recommend the technology for use. Economic considerations are not considered by the HAS, differing from the CVZ, NICE and SMC. Price, in particular, is known by NICE and SMC at time of appraisal, and officially, this is not the case for the HAS. A variable was included in the analysis to capture where price was known up-front during the appraisal or not known (Table 1) .
While a non-recommendation by CVZ, NICE or SMC generally implies no market entry, a non-recommendation from the HAS (ASMR V) does not preclude market entry, as this is driven by the negotiation between the manufacturer and the Comité économique des produits de santé (CEPS). The CEPS is a separate committee that is responsible for finalising the price and volume agreements for technologies. We were not able to include CEPS decision making in our analysis as these negotiations are confidential, to our knowledge, and so we would not be able to analyse the criteria driving CEPS decision making. Other research conducted on the ASMR has made a similar assumption whereby technologies with ASMR V were considered to represent non-recommendation [18] . Further details on how the outcome variable was defined are provided in supplementary material (part 3).
Statistical Analyses
Descriptive statistics were calculated for each variable, stratified by outcome group (recommended, restricted, or not recommended) and we adopted a 0.10 level of significance. For categorical variables, we used the Chi-squared test to test for differences in proportions across the three outcomes. For continuous indicators, we used the ANOVA test to test for differences between means for normally distributed indicators and the Kruskal-Wallis test to identify differences between ranks of means for not normally distributed indicators. It was recognised that collinearity could exist as these variables were included in the multivariate analysis, and thus a step-by-step process was followed to look for evidence of collinearity.
Multinomial logistic regression was used in the analysis to model the probabilities associated with the three types of technology appraisal outcome. Two base cases were examined in multivariate analyses: base case model 1 included all four HTA bodies in the pooled analysis accompanied by fixed effects, and excluded economic variables not common across the four [in particular incremental cost-effectiveness ratio (ICER)-related variables]. Base-case model 2 included HTA bodies (NICE and SMC) that consider the cost effectiveness of technologies to avoid imputation of information that was not formally considered. In the 2004-2009 period, HAS did not consider economic variables and the CVZ was excluded due to low reporting of ICERs within the CVZ appraisals (11 % of appraisals reported ICERs); this is perhaps in part driven by the fact that cost-effectiveness considerations were formally introduced in the CVZ process only in 2006 and cost-effectiveness results are only reported for those technologies that are associated with an incremental therapeutic benefit to patients.
The 'recommended' outcome was selected as the referent category in the analysis. The objective of the analysis was to identify, ceteris paribus, the effect of a range of factors potentially associated with HTA appraisal decisions, and to assess which combination of factors best explains the pattern of HTA decisions. Given the wide range of factors considered in the analysis (see Table 1 ) a process was developed to determine which explanatory variables would appear in the final specification of the model:
• First, bivariate regression models were run to ascertain the degree of correlation between individual explanatory variables and appraisal decisions.
• On the basis of these models, a subset of indicators was selected, which included those variables that showed at least moderate significance levels (indicators with p \ 0.25). A preliminary model was estimated including these indicators.
• The model was reduced by removing those variables with significance levels above the 0.10 threshold. To guarantee its stability, this 'base' model was re-estimated by sequentially removing one variable at a time and verifying the stability of the effects on the coefficient and significance level of the remaining estimates.
• The model was subsequently tested through alternative model specifications to examine its robustness and to assess the sensitivity of the results to different assumptions.
• As a final step, the base-case model results were presented to HTA representatives in 1-h telephone interviews, to seek feedback on the variables identified within the base-case model, the coefficient and level of significance to assess the validity of the model.
The application of the model-specification process outlined above facilitated the interpretation of the results of the models whilst allowing the analysis to explore the impact of the wide range of indicators collected in the study. A step-by-step process was followed to look for evidence of collinearity within the set of regressors.
While significant effort was made to identify information relevant to the variables of interest, a small proportion of the data could not be found. To maximise the sample size, imputation techniques were used to estimate entries for the missing observations. Missing values were replaced with regression imputation estimates using the 'impute' command in STATA software. The imputed values obtained were then checked manually to ensure their face validity. In addition, dummy variables were created to identify observations with missing data to test in the regression models whether the lack of data was significantly associated with differences in the outcome variable.
Sensitivity analyses were performed on the base-case regression model to test for changes in the effects to alternative specifications of the indicators and help evaluate the robustness of the results. The sensitivity analyses included: (1) examining the impact of a binary (coded as: covered/not covered) rather than a three-category outcome variable; (2) examining the impact of including only the sub-set of technologies which were appraised by all four HTA bodies; (3) examining the impact of restricting the analysis to technologies indicated for the treatment of cancer.
Statistical analyses were conducted using Intercooled (IC) STATA (Version 10.1 2009).
Results
Univariate Analyses
In total, 1258 appraisals were reviewed and 977 HTA decisions made in 2004-2009 met the inclusion criteria:
118 NICE decisions, 288 SMC decisions, 256 CVZ decisions and 315 HAS decisions (Fig. 1 ). There were 281 appraisals excluded from the analysis, most commonly because they were abbreviated submissions, or because they focused on non-adult populations (Fig. 1) . Within this data set, 27 % of the decisions recommended funding of the technology, 39 % restricted funding and 35 % did not recommend funding the technology. HTA bodies differed in the pattern of decision making (p \ 0.001, Fig. 2a) . The most common decision by NICE was to restrict funding (58 %), whereas for the CVZ the most common decision was to recommend (51 %). 1 For both the SMC and HAS, the most common decision was to not recommend (46 and 44 %, respectively). When a sub-sample of those technologies common across all four HTA bodies was examined (n = 192, listed in supplementary material, part 4), differences in the pattern of decision making between them was maintained (p \ 0.05, Fig. 2b ). The trends in HTA decisions over time (January 2004-June 2009) for each HTA body are presented in Fig. 3 . These data suggest that within HAS and NICE there has been a decrease in the proportion of positive recommendations made over time and a corresponding increase in the proportion of nonrecommendations. The CVZ and SMC, on the other hand, appear to have maintained a relatively stable pattern of decision making over time.
Univariate analyses showed that within the multi-HTA sample, a range of factors may play an important role in determining HTA decision making. For these variables (Table 2) , statistically significant differences were observed between interventions that were recommended, restricted and not recommended (p B 0.10). Univariate analyses stratified by HTA agency can be found in supplementary material (part 5).
Multivariate Analyses
Base-Case Model 1
Base-case model 1 included 20 variables yielding a pseudo R 2 of 0.13, suggesting that the model explains approximately 13 % of the variability in HTA decisions across the multi-HTA sample (Table 3) .
One of the objectives of this analysis was to assess whether differences between HTA bodies in the pattern of decision making after adjusting for a broad range of covariates. When the impact of NICE, SMC and HAS on HTA decisions was examined relative to the CVZ, the results suggest that NICE and HAS assessment bodies are strongly associated with a decreased odds of a restriction or non-recommendation. This can be contrasted with the effect of the SMC, which was found to statistically significantly increase the log-odds of both restriction and nonrecommendation in all base-case models. The impact of the HTA body was highly statistically significant across all assessments, while adjusting for a range of confounders.
With regard to clinical variables, a higher number of RCTs, and the inclusion of an active comparator in the trial design had a significant impact on the log-odds of recommendation versus restriction or non-recommendation. Specifically, if the technology was compared to an active control rather than placebo, the log-odds for restriction relative to recommendation decreased (p = 0.011), as did the log-odds of non-recommendation relative to recommendation (p = 0.001), while holding all other variables constant. If the technology demonstrated clinical superiority, the log-odds for restriction relative to recommendation decreased (p = 0.023), as did the log-odds of nonrecommendation relative to recommendation (p = 0.001), while holding all other variables constant. Orphan designated pharmaceuticals were less likely to be rejected (p = 0.023).
Process factors had a significant impact on HTA decisions in this multi-HTA analysis. An increase in the number of technologies appraised simultaneously exerted a bigger impact on the log-odds of a restriction (p = 0.002). The inclusion of patient submissions and patient evidence as part of the process was linked with an increase in the log-odds of a restriction (p = 0.008).
Socio-economic factors contributed to explaining the variability in HTA decisions across the HTA bodies. With regard to the size of the population within the HTA body remit, a unit increase in the population size increased the odds of both restriction and non-recommendation, and both effects were statistically significant.
Base-Case Model 2
Base-case model 2 (NICE and SMC) included 19 variables yielding a pseudo R-squared of 0.16, suggesting that the model explains approximately 16 % of the variability in HTA decisions across the multi-HTA sample (Table 4) . With regard to clinical variables, as in base-case model 1, a higher number of RCTs, and the inclusion of an active comparator in the trial design, had a significant impact on the log-odds of recommendation versus restriction or nonrecommendation. Specifically, if the technology was compared to an active control rather than placebo, the logodds for restriction relative to recommendation decreased (p = 0.05), as did the log-odds of non-recommendation relative to recommendation (p = 0.022), while holding all other variables constant. No impact of orphan status was identified in base-case model 2.
With regard to economic variables, a unit increase in the ICER was shown to increase the odds of restriction (p = 0.011) and the log odds of non-recommendation (p = 0.001), relative to recommendation.
Process factors had a significant impact on HTA decisions in this multi-HTA analysis. Relative to recommendation, an increase in the number of technologies significantly increased the odds of both restriction (p = 0.001) and non-recommendation (p = 0.074). No effect on decision was found for either patient submissions or patient evidence.
Socio-economic factors contributed to explaining the variability in decisions across the HTA bodies. A unit increase in the population size within the HTA body remit increased the odds of both restriction and non-recommendation, and both effects were statistically significant.
Sensitivity Analyses
The results of a series of sensitivity analyses suggest that the base-case models are robust. A sensitivity analysis was conducted using a binary outcome variable, providing similar results to the base-case multi-HTA analysis. Sensitivity analyses were also conducted on the sample of technologies indicated for cancer treatment (247 appraisals of 977) as well as on a sub-set of the sample including only those technologies appraised by all four HTA bodies at least once (192 appraisals of 977). The results of these analyses suggest that, compared to the base case model 1, the explanatory power of the combination of clinical, process and socio-economic factors is twice as high when including only those technologies from the same disease area or technologies that all four HTA bodies hold in Fig. 2 common (as implied by the higher pseudo R 2 0.26 and 0.27 in these sub-analyses, respectively, compared with 0.13 in the base-case multi-HTA analysis).
For each HTA agency, a summary of the statistically significant explanatory variables identified in descriptive and multivariate analyses is given in Table 5 .
Discussion
This study aimed to untangle the factors driving funding decisions by conducting multivariate analyses of 977 decisions observed within a multi-HTA data set of appraisals performed by four European HTA agencies: NICE, SMC, CVZ and HAS. Previous comparative analyses across HTA bodies identified in the literature were primarily qualitative or adopted descriptive quantitative methodologies [5, [18] [19] [20] . Such descriptive analytical techniques make it difficult to interpret the relative contribution of each factor, given the absence of adjustment for other factors in the analysis. In contrast, we created a bespoke dataset of HTA coverage decisions from four European HTA bodies over a 5-year period and utilised statistical analysis to assess the relative contribution of a comprehensive range of factors on coverage decisions.
Significant variability in decision making across HTA bodies
Addressing the first objective, the analysis confirmed that observed differences in decision making by HTA agencies remained after adjusting for a range of factors including scoping, evidence considered, process and socio-economic differences. On average, 27 % of the decisions (ranging from 18 % in HAS to 51 % in CVZ) recommended funding of the technology, 39 % restricted funding (range 33 % (Fig. 2a) . Indeed, HTA bodies differ significantly even when the analysis is restricted to coverage decisions made for the same set of technologies (Fig. 2b) . From one perspective, such differences in coverage patterns and the factors that drive decisions can be explained by the fact that each HTA body is designed to match as closely as possible the specific healthcare system it serves. Therefore, variation observed across HTA bodies could be considered to reflect the reality of healthcare market variations between countries. However, from another perspective, differences in the proportion of recommendations, restrictions and non-recommendations might be seen to be contrary to the principle of equitable access to treatment in Europe.
In particular, non-recommendation was observed in 14 and 16 % of NICE and CVZ coverage decisions, and 44 and 46 % of HAS and SMC coverage decisions, respectively. These technologies were not recommended for reimbursement despite obtaining a license for use within Europe from regulatory agencies, primarily the European Medicines Agency (EMA). Differences in the criteria used to assess the value of new technologies between the EMA and HTA bodies could be seen as a key driver of this situation. This suggests there could be potential for efficiencies in the regulatory and HTA processes so that effort is not spent on generating marketing authorisations for a significant proportion of technologies that end up not being recommended for reimbursed use by HTA bodies. The second objective of this analysis was to explore the factors that contribute to explaining the variability in coverage decisions made by the four HTA bodies in [2004] [2005] [2006] [2007] [2008] [2009] . The degree of 'untangling' achieved was limited given that multivariate analyses could only explain between 13 and 30 % of the observed variability in decision making, despite taking into account a wide range of variables. A higher proportion of the variability could be explained when limiting the analysis to a common set of technologies evaluated by all HTA bodies. This suggests that the variability in HTA outcomes may in part be driven by the heterogeneity observed in the technologies selected for appraisal. However, even when this heterogeneity is managed by focusing the multivariate analysis on a subset of technologies that are either commonly appraised across HTAs or focus on a single disease area, more than 70 % of the variability in decision making could not be explained. Indeed, whether the technology was appraised by one HTA or another was found to have a statistically significant effect on the outcome, even when adjusting for a range of confounding factors. Relative to the CVZ, the results suggest that NICE and HAS are associated with a higher probability of recommendation, while the SMC is associated with a higher probability of both restriction and nonrecommendation. This may be due to the fact that the HTA body is surrogate for other variables and thus that additional variables needed to be included, alternative methods of analysis tested, and/or that decision making is partly random. This result echoes in part results from Clement et al. [5] reporting statistically significant differences in the nature of the HTA decisions made by NICE, Australian Pharmaceutical Benefits Advisory Committee (PBAC) and Common Drug Review (CDR). Our analysis would support the view that while evidence-based assessment of technologies is a key part of the HTA process, decision making is ultimately driven by a range of factors that appear to be highly specific to each HTA body.
The strength of the evidence demonstrating the clinical value of the pharmaceutical, together with the therapeutic area which it targets, have a significant role in HTA decisions. Interestingly, there were some specific variables which appeared to have an impact (such as demonstration of clinical superiority), while other clinical/disease evidence variables did not show any effect in the multivariate analyses (e.g. number of observational studies). This raises the question of whether it would be of benefit for HTA bodies and manufacturer submissions (and clinical trials) to streamline the submission and review of clinical evidence that most drives decision making, encouraging more efficient HTA assessments. There were no other published cross-HTA multivariate studies available for comparison, although single-HTA analyses have identified a range of clinical evidence characteristics associated with HTA outcomes [21] .
The multi-HTA analysis of NICE and SMC appraisals (more than 400 of which were analysed here), representing one of the largest analyses of the effect of cost effectiveness on HTA decision making, confirmed the hypothesis that the effect of the ICER is similar to that observed in individual HTA analyses [6, 7, 22] : a higher ICER decreases the probability of recommendation, an effect that is highly statistically significant in our analyses. While CVZ and HAS were excluded from this analysis due to limited consideration (CVZ) 2 or no consideration (HAS) of cost-effectiveness evidence, since the time of this analysis both HTA bodies have increased the role of economic criteria in their decision making.
This multi-HTA analysis finds support for the role of process factors in explaining decision making, in particular the role of patient evidence, and the impact of single versus multi-technology appraisals. The multivariate analyses confirmed that an increase in the number of technologies appraised simultaneously increased the probability of restriction and non-recommendation. This would suggest that in circumstances where multiple technologies are being appraised simultaneously, a 'winner' is more likely to be selected, with the remainder being restricted or not recommended for funding. This has implications when considering the efficiencies that may be gained in the appraisal process by coupling the review of multiple technologies together, against the time-lag that this may create in access to new medicines, depending on how frequently multi-technology reviews are conducted.
National population size had a significant impact on HTA decision making in this multi-HTA analysis, an effect not previously observed in individual HTA analyses [5, 6, 22] . Greater population size decreased the probability of recommendation. It is not clear to what extent this reflects the effect of the absolute size of the patient population eligible for treatment: this variable also increases the odds of restriction and non-recommendation, but its effect is only significant in base-case model 1 (on odds of restriction relative to recommendation). It is plausible that population size may serve as a proxy for the budget impact of adopting a technology, but when the budget impact variable was introduced in additional sensitivity analyses, it was not significant.
Limitations
We focused specifically on pharmaceutical technologies as we wanted to generate a sample of technologies representative of the majority of decisions made by the HTA bodies included in the study. Thus results of this analysis are not readily generalizable to non-pharmaceutical technologies. The selection of HTA bodies for inclusion in this analysis was driven by the objectives of the study, and in addition, HTA bodies were selected that reported their appraisals in English, French or Dutch (to make it feasible for us to collect our primary data).
The potential for information bias, particularly in how the outcome and explanatory variables were defined and extracted for each HTA body, was recognised, and a data extraction protocol and process was defined to limit inconsistencies in the extraction process. However, there are still limitations. In particular, decisions are communicated differently across HTA bodies: HAS uses ASMR ratings to define incremental therapeutic value, CVZ attributes technologies to different reimbursement lists, SMC uses a three-category system and NICE a binary category system. In addition, the use of the 'restricted' category in this analysis is challenged by the fact that inter-and intra-HTA differences exist in how it is applied.
The generalizability of the results is further constrained by the fact that HTA appraisal processes are subject to change (for example, the potential introduction of valuebased pricing in UK in 2014, changes in France with increasing consideration for medico-economic evidence in 2013), and thus the results obtained are specific to [2004] [2005] [2006] [2007] [2008] [2009] . HTA bodies, both within and outside Europe, vary in their objectives, and in the approach and methods used to implement HTA within their jurisdictions.
Socio-economic indicators such as GDP are known to be influenced by many different factors. Indeed, such indicators act as a surrogate for many characteristics of the countries to which they apply. In addition, such indicators that vary at the HTA body level, rather than the technology appraisal level, are unlikely to have a very strong effect, due to the limited number of HTA bodies in this analysis. Therefore, the interpretation of the impact of such broad indicators, such as the percentage of GDP spent on healthcare, will need to take into consideration the risk that variations observed in such indicators across HTA bodies may be correlated with other factors.
Given the heterogeneity in decision making observed in this analysis, extrapolating to other HTA bodies not included in this research is not advisable without having a more concrete understanding of their decision-making processes and the outcome definition used.
Implications
This analysis involved an intensive data collection exercise lasting 18 months: information about HTA decision making and the characteristics of a technology, the appraisal process and the context in which decisions are made, is not readily available. It raises interesting questions about the role of transparency in decision making, in particular to what extent any transparency which exists at the level of individual technology appraisals should be extended to transparency in the outcome and drivers of decision making for the decisions made by HTA bodies.
The implications of this analysis in the light of the increasing collaboration between European HTA bodies through EUnetHTA should be addressed. A key project ongoing within EUnetHTA is the HTA Core Model for Rapid Relative Effectiveness Assessment of Pharmaceuticals: the ''HTA Core Model defines the content elements to be considered in an HTA and facilitates standardised reporting. The aim is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-production of HTA reports (by multiple HTA agencies)'' (EUnetHTA accessed 2013). This core-model concept assumes that there is overlap in the timing of when pharmaceutical appraisals take place, and overlap in the scoping practices of HTA bodies. In the sample covered in this study, only 10 % of technologies were appraised by all four HTA bodies, and significant differences in the timing of appraisals were observed. This has implications in terms of the co-ordination and timing of centralised HTA Core Model initiatives to ensure that they have maximum relevance to the HTA stakeholders they wish to serve. This analysis may also help to inform which types of evidence might best be included in the Core Model, based on those variables which appear to have the most effect in explaining payer decisions.
The framework adopted in our analysis, notwithstanding its limitations, provides an example of a comprehensive analytical approach for understanding coverage decision making. While recognising the diversity in scope, objective and context in which different HTA bodies operate, convergence towards an analytical framework for the analysis of coverage decisions in future research may be of value.
Conclusions
In this European multi-HTA study, a comprehensive and multivariate analytical approach found that clinical, process, socio-economic factors and an ''HTA-agency effect'' explained part of the observed variability in HTA decisions, helping to untangle some aspects of decision making. However, this extensive analysis of HTA decision making could explain no more than 30 % of the observed variability, suggesting that while some aspects of decision making have been 'untangled', greater transparency of decision making is needed, along with associated further research.
